tetano
Editor, Senior Moderator
Cell Rep
. 2022 Oct 27;111650.
doi: 10.1016/j.celrep.2022.111650. Online ahead of print.
Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2
Meng Yuan[SUP] 1 [/SUP], Yiquan Wang[SUP] 2 [/SUP], Huibin Lv[SUP] 3 [/SUP], Timothy J C Tan[SUP] 4 [/SUP], Ian A Wilson[SUP] 5 [/SUP], Nicholas C Wu[SUP] 6 [/SUP]
Affiliations
Abstract
As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concerns (VOCs) continue to emerge, cross-neutralizing antibody responses become key toward next-generation design of a more universal COVID-19 vaccine. By analyzing published data from the literature, we report here that the combination of germline genes IGHV2-5/IGLV2-14 represents a public antibody response to the receptor-binding domain (RBD) that potently cross-neutralizes a broad range of VOCs, including Omicron and its sub-lineages. Detailed molecular analysis shows that the complementarity-determining region H3 sequences of IGHV2-5/IGLV2-14-encoded RBD antibodies have a preferred length of 11 amino acids and a conserved HxIxxI motif. In addition, these antibodies have a strong allelic preference due to an allelic polymorphism at amino acid residue 54 of IGHV2-5, which is located at the paratope. These findings have important implications for understanding cross-neutralizing antibody responses to SARS-CoV-2 and its heterogenicity at the population level as well as the development of a universal COVID-19 vaccine.
Keywords: COVID-19; CP: Immunology; CP: Microbiology; SARS-CoV-2; allelic preference; broadly neutralizing; data mining; public antibody; sequence analysis; variants of concern.
. 2022 Oct 27;111650.
doi: 10.1016/j.celrep.2022.111650. Online ahead of print.
Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2
Meng Yuan[SUP] 1 [/SUP], Yiquan Wang[SUP] 2 [/SUP], Huibin Lv[SUP] 3 [/SUP], Timothy J C Tan[SUP] 4 [/SUP], Ian A Wilson[SUP] 5 [/SUP], Nicholas C Wu[SUP] 6 [/SUP]
Affiliations
- PMID: 36335937
- DOI: 10.1016/j.celrep.2022.111650
Abstract
As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concerns (VOCs) continue to emerge, cross-neutralizing antibody responses become key toward next-generation design of a more universal COVID-19 vaccine. By analyzing published data from the literature, we report here that the combination of germline genes IGHV2-5/IGLV2-14 represents a public antibody response to the receptor-binding domain (RBD) that potently cross-neutralizes a broad range of VOCs, including Omicron and its sub-lineages. Detailed molecular analysis shows that the complementarity-determining region H3 sequences of IGHV2-5/IGLV2-14-encoded RBD antibodies have a preferred length of 11 amino acids and a conserved HxIxxI motif. In addition, these antibodies have a strong allelic preference due to an allelic polymorphism at amino acid residue 54 of IGHV2-5, which is located at the paratope. These findings have important implications for understanding cross-neutralizing antibody responses to SARS-CoV-2 and its heterogenicity at the population level as well as the development of a universal COVID-19 vaccine.
Keywords: COVID-19; CP: Immunology; CP: Microbiology; SARS-CoV-2; allelic preference; broadly neutralizing; data mining; public antibody; sequence analysis; variants of concern.